Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Chronic Neuropathic Pain Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Chronic Neuropathic Pain clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
VXA-CoV2-3.3 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
VXA-CoV2-3.3: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Obsessive-Compulsive Disorder Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Obsessive-Compulsive Disorder clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…
8 min read
RAD21 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for RAD21, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
ORKA-002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
ORKA-002: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Generalized Anxiety Disorder Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Generalized Anxiety Disorder clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white...
Latest Hotspot
8 min read
Pamapimod Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Pamapimod/Pioglitazone: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Post-Traumatic Stress Disorder Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Post-Traumatic Stress Disorder clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development…
Latest Hotspot
8 min read
Schizophrenia Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Schizophrenia clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Segatroxaban Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Segatroxaban: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Bipolar Depression Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Bipolar Depression clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Icalcaprant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Icalcaprant: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.